by Alison Bass | Feb 21, 2011 | Uncategorized
I’m embarrassed to admit that when I was a medical reporter for The Boston Globe in the ’90s, I (along with many other journalists) would unthinkingly use the $800 million that the pharmaceutical industry said it cost to develop a new drug product....
by Alison Bass | Feb 10, 2011 | Uncategorized
There must be something in the air. Either that, or the drug and medical device industry has embarked on a concerted campaign to improve its tattered public image and bully the FDA into backing down from recent efforts to ensure that unsafe drugs and medical devices...
by Alison Bass | Feb 2, 2011 | Uncategorized
The Journal of the American Academy of Child and Adolescent Psychiatry has refused to retract a study finding that the antidepressant Paxil was safe and effective in adolescents despite evidence of fabrication, plagiarism and failure to disclose conflicts of interest...
by Alison Bass | Jan 21, 2011 | Uncategorized
The retraction of questionable scientific papers seems to be on the rise, due in large part to increased media scrutiny of scientific misconduct and conflicts of interest among researchers who fail to disclose they have skin in the game, i.e. lucrative financial ties...
by Alison Bass | Jan 18, 2011 | Uncategorized
On Wednesday, Jan. 19, I’m moderating a panel on blogging about health and science, sponsored by the New England Science Writers. We are fortunate to have attracted some top-notch bloggers, including Gary Schwitzer, whose HealthNewsReview blog was named the best...
by Alison Bass | Jan 12, 2011 | Uncategorized
For weeks now, The Boston Globe has been running stories about Sanofi Aventi’s hostile bid to acquire Genzyme, the Boston-based biotech giant. One recent story talked about how the CEOs of both companies attended the same conference in San Francisco without...
